Skip to main content

Airbus CEO Guillaume Faury says escalating trade tensions will harm the global aerospace industry.

PIROSCHKA VAN DE WOUW/Reuters

The head of Europe’s Airbus SE says it is too early to talk about acquiring a Belfast factory placed on sale by Montreal-based Bombardier Inc.

Bombardier said this month that it would sell the plant, which makes wings for the C Series jet. Airbus bought the money-losing C Series program from Bombardier last year while leaving it with control of the aerostructures operations.

Analysts have said the plant could be attractive to Airbus, but CEO Guillaume Faury told reporters on Thursday that the discussion was “premature.”

Story continues below advertisement

The C Series, renamed the A220, is the first commercial aircraft to use a new form of carbon-fibre manufacturing called resin transfer infusion.

Current models of lightweight planes such as the Boeing 787 Dreamliner and Airbus A350 are built from carbon fibre impregnated with resin, called “prepreg.” This is tailored into plane parts and cured inside pressurized ovens or autoclaves.

Under the new technology, instead of using fibre that is pre-impregnated with resin, parts are made from a dry textile which is placed in a mould and then infused with resin in the factory to reduce waste and speed production.

The next step is to dispense with the energy-hungry and bulky autoclaves as Russia has begun doing with its MC-21 jet.

Airbus is interested in both stages of the new technology as it prepares for high-speed composite jet production, industry sources say. It has called the plant a “key supplier” but declined to say if it would buy it or a sister plant in Morocco.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter